Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Interscope Endorotor® Mucosal Resection System With Continued Ablative Therapy In Subjects With Refractory Dysplastic Barrett's Esophagus

NCT03364114 is registered in ClinicalTrials.gov with Interscope, Inc. as lead sponsor.

NCT NCT03364114
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03364114 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Interscope Endorotor® Mucosal Resection System With Continued Ablative Therapy In Subjects With Refractory Dysplastic Barrett's Esophagus
Lead sponsor
Interscope, Inc.
Phase
Not applicable
Overall status
Terminated
Start date
February 9, 2018
Completion date
March 24, 2026
Enrollment
15 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

barrett's esophagus with dysplasia